Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 250-255

  Jacobs, Shana S ^a,b,d   Stork, Linda C ^c   Bostrom, Bruce C ^f   Hutchinson, Ray ^g   Holcenberg, John ^h   Reaman, Gregory H ^a,i   Erdmann, Gary ^j   Franklin, Janet ^k   Neglia, Joseph P ^l   Steinberg, Seth M ^d   Balis, Frank M ^b   Adamson, Peter C ^e  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

ⁱ CHILDREN S ONCOLOGY GROUP   (United States)

^j PRACS Institute Ltd   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Thioguanine nucleotides; Thiopurines; Veno occlusive disease

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; BRAIN LEUKEMIA; CANCER RELAPSE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SIDE EFFECT; SINUSOIDAL OBSTRUCTION SYNDROME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PILOT PROJECTS; SURVIVAL ANALYSIS; THIOGUANINE;

EID: 34547770299     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20964     Document Type: Article

References (32)

1. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-292.
2. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994;18:805-810.
3. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998;42:266-272.
4. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 1981;6:35-38.
5. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983;308:1005-1009.
6. Kitchen BJ, Balis FM, Poplack DG, et al. A pediatric phase i trial and pharmacokinetic study of thioguanine administered by continuous i.V. Infusion. Clin Cancer Res 1997;3:713-717.
7. Zimm S, Ettinger LJ, Holcenberg JS, et al. Phase i and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985;45:1869-1873.
8. Lowe ES, Kitchen BJ, Erdmann G, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: A collaborative pediatric oncology branch, nci, and children's cancer group study. Cancer Chemother Pharmacol 2001;47:199-205.
9. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A childrens cancer group phase iii trial. J Clin Oncol 1993;11:527-537.
10. Erdmann GR, France LA, Bostrom BC, et al. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990;4:47-51.
11. Weinshilboum R, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-333.
12. Hollander M, Wolfe D. Nonparametric statistical methods. New York: John Wiley and sons; 1999. pp 189-269.
13. Agresti A. Categorical data analysis. New York: John Wiley and Sons, Inc.; 1990. pp 79-129.
14. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the children's cancer group. Blood 2003;101:3809-3817.
15. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003;21:1798-1809.
16. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A childrens cancer group report. J Clin Oncol 1993;11:520-526.
17. Stork LC, Sather H, Hutchinson R, et al. Comparison of mercaptoputine (mp) with thioguanine (tg) an it methotrexate with it "triples" (itt) in children with sr-all: Results of ccg-1952. Abstracts of the American Society of Hematology 2002;585.
18. Bell BA, Brockway GN, Shuster JJ, et al. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A pediatric oncology group study (now the children's oncology group). Pediatr Blood Cancer 2004;43:105-109.
19. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-1823.
20. Lancaster DL, Lennard L, Rowland K, et al. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: A comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998;102:439-443.
21. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993;15:80-86.
22. Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002;62:102-109.
23. Evans WE, Relling MV. Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res 1994;18:811-814.
24. Broxson EH, Dole M, Wong R, et al. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 2005;44:1-6.
25. Vora A, Mitchell C, Kinsey S, et al. Thioguanine-related veno-occlusive disease (vod) of the liver in children with acute lymphoblastic leukemia (ALL): Report from the united kingdom medical research council (uk mrc) trial ALL97. Abstracts of the American Society of Hematology 2002;126.
26. Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003;123:100-102.
27. Piel B, Vaidya S, Lancaster D, et al. Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2004;125:410-411 (author reply 412).
28. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298-303.
29. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92. Blood 2003;102:2736-2740.
30. Woods W, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the children's cancer group. Blood 1996;87:4979-4989.
31. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric oncology group. N Engl J Med 1996;334:1428-1434.
32. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of dat versus ade as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council's 10th aml trial (mrc aml10). Adult and childhood leukaemia working parties of the medical research council. Blood 1997;89:2311-2318.